

| Número de catálogo | HB038056 |
|---|---|
| Reactividad de especies | Human |
| Aplicaciones | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Especie huésped | Human |
| Clonalidad | Monoclonal |
| Isotipo | IgG |
| ID de clon | HeFi-1 |
| Actividad biológica | HeFi-1 (0.1 ng/uL, 1 h) can bind specifically to Karpas299 cells with a binding rate of over 90 % [1]. HeFi-1 (20 ug/mL, 48 h) can significantly inhibit the proliferation of Karpas299 cells and induces G1 phase blockade [1]. HeFi-1 (20 ug/mL, 12-24 h) can significantly induce apoptosis in eosinophil [2]. Cell Proliferation Assay [1] Cell Line: Karpas299 cells Concentration: 20 ug/mL Incubation Time: 48 h Result: Significantly inhibited cell proliferation with an inhibition rate of 40%, superior to Daclizumab (). Cell Cycle Analysis [1] Cell Line: Karpas299 cells Concentration: 20 ug/mL Incubation Time: 48 h Result: Induced G1 phase arrest and a decrease in S phase cells. HeFi-1 (100 ug, i.v., once weekly, for 4 weeks) can effectively prolong survival in SCID/NOD wild-type and FcRγ -/- mice bearing Karpas299 lymphoma [1]. |
| Sistema de expresión | Mammalian cells |
| Objetivo | CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30 |
| Nivel de endotoxinas | < 10 EU/mg |
| Pureza | >95% purity as determined by SDS-PAGE. |
| Purificación | Protein A/G purified from cell culture supernatant. |
| Número de acceso | P28908 |
| Forma | Liquid |
| Buffer de almacenamiento | 0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote. |
| Estabilidad y almacenamiento | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Nombres alternativos | HeFi-1, HeFi1, HeFi1 |
| Fondo | Tumor necrosis factor receptor superfamily member 8 (CD30/TNFRSF8) is a ~63 kDa protein. Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. CD30 is the therapeutic target of brentuximab vedotin (Adcetris). 1. Smith, CA. et al. (1993) Cell 73, 1349-60. PMID: 8391931 2. Aizawa, S. et al. (1997) The Journal of biological chemistry 272, 2042-5. PMID: 8999898 |
| Referencias | 1. Zhang M, et al. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood. 2006 Jul 15;108(2):705-10. [HB038056] 2. Berro AI, et al. Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol. 2004 Aug 1;173(3):2174-83. [HB038056] |
| Nota | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human CD30/TNFRSF8 (HeFi-1)




Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.
Correo: [email protected]


+86-027-65523339
Edificio C, No. 666, Calle Shendunsi, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский